WO2002100433A1 - Medicinal compositions - Google Patents
Medicinal compositions Download PDFInfo
- Publication number
- WO2002100433A1 WO2002100433A1 PCT/JP2002/005726 JP0205726W WO02100433A1 WO 2002100433 A1 WO2002100433 A1 WO 2002100433A1 JP 0205726 W JP0205726 W JP 0205726W WO 02100433 A1 WO02100433 A1 WO 02100433A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- compound
- group
- pyridyl group
- inhibiotry
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20020733431 EP1402900A1 (en) | 2001-06-11 | 2002-06-10 | Medicinal compositions |
US10/480,551 US20050080113A1 (en) | 2001-06-11 | 2002-06-10 | Medicinal compositions |
CA002450400A CA2450400A1 (en) | 2001-06-11 | 2002-06-10 | Medicinal compositions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001175273 | 2001-06-11 | ||
JP2001-175273 | 2001-06-11 | ||
JP2001-175224 | 2001-06-11 | ||
JP2001175224 | 2001-06-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002100433A1 true WO2002100433A1 (en) | 2002-12-19 |
Family
ID=26616680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/005726 WO2002100433A1 (en) | 2001-06-11 | 2002-06-10 | Medicinal compositions |
Country Status (4)
Country | Link |
---|---|
US (1) | US20050080113A1 (ja) |
EP (1) | EP1402900A1 (ja) |
CA (1) | CA2450400A1 (ja) |
WO (1) | WO2002100433A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004021988A2 (en) * | 2002-09-05 | 2004-03-18 | Scios Inc. | Treatment of pain by inhibition of p38 map kinase |
WO2004026307A1 (en) * | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
WO2006137658A1 (en) * | 2005-06-20 | 2006-12-28 | Dongbu Hitek Co., Ltd. | New substituted 1,3-thiazole derivatives or pharmaceutically acceptable salts thereof having immunosuppression and inflammation inhibitory acitivity, intermediate compounds or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and pharmaceutical composition comprising the same |
WO2006137527A1 (ja) | 2005-06-23 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | チアゾール誘導体 |
US7273936B2 (en) | 2002-09-18 | 2007-09-25 | Pfizer Inc. | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors |
US7410988B2 (en) | 2004-08-13 | 2008-08-12 | Genentech, Inc. | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
US8049016B2 (en) | 2008-02-20 | 2011-11-01 | Novartis Ag | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes |
US8063084B2 (en) | 2006-08-15 | 2011-11-22 | Novartis Ag | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels |
US20130267509A1 (en) * | 2003-12-26 | 2013-10-10 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivatives |
US9663529B2 (en) | 2013-07-02 | 2017-05-30 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
US9914740B2 (en) | 2013-07-02 | 2018-03-13 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
CN111757881A (zh) * | 2018-01-15 | 2020-10-09 | 澳升控股有限公司 | 作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物 |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7101899B1 (en) * | 1999-04-23 | 2006-09-05 | Takeda Pharmaceutical Company Limited | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof |
US8273347B2 (en) * | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
US7344716B2 (en) * | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US7429378B2 (en) * | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
US7137864B2 (en) * | 2004-07-12 | 2006-11-21 | Swanson Melvin J | Methods and reagents for treating honeybees for parasitic mites |
WO2006051826A1 (ja) | 2004-11-10 | 2006-05-18 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
AU2005314133B2 (en) | 2004-12-06 | 2012-03-08 | Medicinova, Inc. | Ibudilast for treating neuropathic pain and associated syndromes |
CA2636077C (en) * | 2006-01-18 | 2012-01-03 | Amgen Inc. | Thiazole compounds as protein kinase b (pkb) inhibitors |
CH698658B1 (de) * | 2006-04-24 | 2009-09-30 | Mepha Ag | Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole. |
US20080181876A1 (en) * | 2007-01-30 | 2008-07-31 | Johnson Kirk W | Methods for treating acute and subchronic pain |
US20080287402A1 (en) * | 2007-05-03 | 2008-11-20 | Johnson Kirk W | Use of a glial attenuator to prevent amplified pain responses caused by glial priming |
CA2693473A1 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
AU2008276521B2 (en) | 2007-07-17 | 2011-11-03 | Amgen Inc. | Heterocyclic modulators of PKB |
US8986696B2 (en) * | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
US20090162351A1 (en) * | 2007-12-21 | 2009-06-25 | Depuy Spine, Inc. | Transdiscal administration of inhibitors of p38 MAP kinase |
EP2268268A2 (en) * | 2008-03-24 | 2011-01-05 | Wockhardt Research Centre | Orally disintegrating compositions of rhein or diacerein |
RU2011108420A (ru) * | 2008-08-14 | 2012-09-20 | Киорин Фармасьютикал Ко., Лтд. (Jp) | Стабилизированный фармацевтический состав |
EP2198710A1 (de) * | 2008-12-19 | 2010-06-23 | Bayer CropScience AG | Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze |
US20130137728A1 (en) * | 2010-03-24 | 2013-05-30 | MUSC Foundation for Research and Development | Compositions and Methods for the Treatment of Degenerative Diseases |
WO2012085650A1 (en) * | 2010-12-22 | 2012-06-28 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
JP6527305B2 (ja) | 2011-01-10 | 2019-06-05 | インヴィオン, インコーポレイテッド | 禁煙のためのβ−アドレナリン作動性インバースアゴニストの使用 |
AU2012320578B2 (en) | 2011-10-06 | 2017-03-02 | Bayer Intellectual Property Gmbh | Heterocyclylpyri(mi)dinylpyrazole |
EP2763987B1 (en) | 2011-10-06 | 2018-07-18 | Bayer CropScience AG | Heterocyclylpyri(mi)dinylpyrazole as fungicidals |
KR101665231B1 (ko) * | 2015-01-30 | 2016-10-13 | 순천향대학교 산학협력단 | 티오페닐 그룹을 갖는 티아졸계 화합물 및 이를 유효성분으로 포함하는 항진균제 |
EP3325473A4 (en) * | 2015-07-22 | 2019-06-26 | The Royal Institution for the Advancement of Learning / McGill University | Compounds and uses thereof in the treatment of cancer and other medical disorders |
US20180296478A1 (en) * | 2016-02-12 | 2018-10-18 | Synergistic Therapeutics, Llc | Sublingual antidepressant and antianxiety tablet |
CN107050021B (zh) * | 2017-01-23 | 2019-11-26 | 广州中大南沙科技创新产业园有限公司 | 噻唑酰胺衍生物在制备抗骨质疏松药物中的应用 |
CN109293652B (zh) * | 2017-07-24 | 2021-10-22 | 四川科伦博泰生物医药股份有限公司 | 一种取代的噻唑衍生物及其用途 |
CN109730999B (zh) * | 2018-12-28 | 2021-12-24 | 中山大学 | 噻唑苯甲酰胺衍生在制备抗骨质疏松、抗骨关节炎药物中的应用 |
CN109939109B (zh) * | 2018-12-28 | 2021-03-23 | 中山大学 | N-噻唑-乙酰胺衍生物作为破骨细胞分化抑制剂在制备抗骨质疏松药物中的应用 |
GB202011996D0 (en) * | 2020-07-31 | 2020-09-16 | Adorx Therapeutics Ltd | Antagonist compounds |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063204A2 (en) * | 1999-04-14 | 2000-10-26 | Novartis Ag | Substituted azoles |
WO2000064894A1 (fr) * | 1999-04-23 | 2000-11-02 | Takeda Chemical Industries, Ltd. | Composes 5-pyridyle-1,3-azole, leur procede de fabrication et leur utilisation |
WO2000075131A1 (fr) * | 1999-06-03 | 2000-12-14 | Teikoku Hormone Mfg. Co., Ltd. | Composes a base de pyrazole substitue |
WO2001001986A1 (en) * | 1999-07-02 | 2001-01-11 | Lipton Stuart A | Method of reducing neuronal injury or apoptosis |
WO2001010865A1 (fr) * | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | INHIBITEURS DE p38MAP KINASE |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046208A (en) * | 1996-01-11 | 2000-04-04 | Smithkline Beecham Corporation | Substituted imidazole compounds |
-
2002
- 2002-06-10 CA CA002450400A patent/CA2450400A1/en not_active Abandoned
- 2002-06-10 US US10/480,551 patent/US20050080113A1/en not_active Abandoned
- 2002-06-10 WO PCT/JP2002/005726 patent/WO2002100433A1/ja not_active Application Discontinuation
- 2002-06-10 EP EP20020733431 patent/EP1402900A1/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063204A2 (en) * | 1999-04-14 | 2000-10-26 | Novartis Ag | Substituted azoles |
WO2000064894A1 (fr) * | 1999-04-23 | 2000-11-02 | Takeda Chemical Industries, Ltd. | Composes 5-pyridyle-1,3-azole, leur procede de fabrication et leur utilisation |
WO2000075131A1 (fr) * | 1999-06-03 | 2000-12-14 | Teikoku Hormone Mfg. Co., Ltd. | Composes a base de pyrazole substitue |
WO2001001986A1 (en) * | 1999-07-02 | 2001-01-11 | Lipton Stuart A | Method of reducing neuronal injury or apoptosis |
WO2001010865A1 (fr) * | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | INHIBITEURS DE p38MAP KINASE |
Non-Patent Citations (2)
Title |
---|
CHU I. ET AL.: "Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes", RAPID COMMUN. MASS. SPECTROM., vol. 14, no. 4, 2000, pages 207 - 214, XP002955900 * |
MATSUMOTO MASAHITO ET AL.: "Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor", FEBS LETTERS, vol. 486, no. 1, 2000, pages 23 - 28, XP002955899 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004021988A3 (en) * | 2002-09-05 | 2004-08-26 | Scios Inc | Treatment of pain by inhibition of p38 map kinase |
WO2004021988A2 (en) * | 2002-09-05 | 2004-03-18 | Scios Inc. | Treatment of pain by inhibition of p38 map kinase |
WO2004026307A1 (en) * | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
US7053095B2 (en) | 2002-09-18 | 2006-05-30 | Pfizer Inc. | Triazole compounds as transforming growth factor (TGF) inhibitors |
US7273936B2 (en) | 2002-09-18 | 2007-09-25 | Pfizer Inc. | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors |
US20130267509A1 (en) * | 2003-12-26 | 2013-10-10 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivatives |
US8889718B2 (en) * | 2003-12-26 | 2014-11-18 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivatives |
US7410988B2 (en) | 2004-08-13 | 2008-08-12 | Genentech, Inc. | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
US7795290B2 (en) | 2004-08-13 | 2010-09-14 | Genentech, Inc. | 2-amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
WO2006137658A1 (en) * | 2005-06-20 | 2006-12-28 | Dongbu Hitek Co., Ltd. | New substituted 1,3-thiazole derivatives or pharmaceutically acceptable salts thereof having immunosuppression and inflammation inhibitory acitivity, intermediate compounds or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and pharmaceutical composition comprising the same |
WO2006137527A1 (ja) | 2005-06-23 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | チアゾール誘導体 |
US8063084B2 (en) | 2006-08-15 | 2011-11-22 | Novartis Ag | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels |
US8293768B2 (en) | 2006-08-15 | 2012-10-23 | Novartis Ag | Organic compounds |
US8318949B2 (en) | 2008-02-20 | 2012-11-27 | Novartis Ag | Organic compounds |
US8049016B2 (en) | 2008-02-20 | 2011-11-01 | Novartis Ag | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes |
US9663529B2 (en) | 2013-07-02 | 2017-05-30 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
US9914740B2 (en) | 2013-07-02 | 2018-03-13 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
CN111757881A (zh) * | 2018-01-15 | 2020-10-09 | 澳升控股有限公司 | 作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物 |
JP2021510704A (ja) * | 2018-01-15 | 2021-04-30 | オーセントラ ホールディングス ピーティーワイ エルティーディーAucentra Holdings Pty Ltd | 治療薬としての5−(ピリミジン−4−イル)チアゾール−2−イル尿素誘導体 |
JP7406808B2 (ja) | 2018-01-15 | 2023-12-28 | オーセントラ セラピュティクス ピーティーワイ エルティーディー | 治療薬としての5-(ピリミジン-4-イル)チアゾール-2-イル尿素誘導体 |
Also Published As
Publication number | Publication date |
---|---|
CA2450400A1 (en) | 2002-12-19 |
US20050080113A1 (en) | 2005-04-14 |
EP1402900A1 (en) | 2004-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002100433A1 (en) | Medicinal compositions | |
WO2002010137A3 (en) | Indazole derivatives as JNK inhibitors | |
EP1205478A4 (en) | P38MAP KINASE INHIBITORS | |
WO2004105757A3 (en) | Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy | |
PL1784404T3 (pl) | Pochodne pirolo[2,3-c]pirydyny i sposoby ich wytwarzania | |
WO2002046171A3 (en) | Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto | |
WO2001005390A3 (en) | Method for treating chronic pain using mek inhibitors | |
WO2005047244A3 (en) | Inhibition of fgfr3 and treatment of multiple myeloma | |
WO2001072728A3 (en) | Novel piperazine derivatives | |
AU2721402A (en) | Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto | |
WO2003065992A3 (en) | Treating benign prostate hyperplasia with sarms | |
WO2004018419A3 (en) | Benzimidazole quinolinones and uses thereof | |
WO2005079795A3 (en) | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders | |
WO1999005096A3 (en) | Urokinase inhibitors | |
AU6945601A (en) | Benzoylpyridine derivative or its salt, fungicide containing it as an active ingredient, its production process and intermediate for producing it | |
HK1105977A1 (en) | Pyrrolo [3,2-c] pyridine derivatives and processes for the preparation | |
WO2001085201A3 (en) | Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis | |
WO2001056573A8 (en) | Use of cox-2 inhibitors as gastroprokinetics | |
WO2002016312A3 (de) | NEUE VERBINDUNGEN, DIE FAKTOR Xa-AKTIVITÄT INHIBIEREN | |
WO2004021988A3 (en) | Treatment of pain by inhibition of p38 map kinase | |
AU2002232400A1 (en) | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | |
WO2003037863A3 (de) | Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung | |
WO2004009030A3 (en) | Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof | |
WO2003035613A3 (en) | Nitrogen heterocycle inhibitors of aspartyl protease | |
EP2016944A3 (en) | Angiogenesis inhibitor containing a derivative of rifampicin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2450400 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10480551 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002733431 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002733431 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002733431 Country of ref document: EP |